top of page

Search Results

Results found for "Omass Therapeutics"

  • Qing Fan: Inside the Architecture of Class C GPCRs | Dr. GPCR Ecosystem

    Her work employs X-ray crystallography, single-particle cryo-EM, mutagenesis, and mass spectrometry, mutations in the GABA-B transmembrane domain and what they suggest about precision pharmacology The therapeutic Using mass spectrometry in collaboration with colleagues at UC Davis, they identified the exact molecular But its therapeutic window is narrow.

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They shared their unconventional approaches to research, including the creation of a critical mass of Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They shared their unconventional approaches to research, including the creation of a critical mass of Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic

  • Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem

    Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

  • GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem

    into industry, and his role leading and shaping multidisciplinary teams for screening and innovative therapeutics How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Marro’s career advanced through roles at Novartis and Tectonic Therapeutic, contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases.

  • Chris Langmead | Dr. GPCR Ecosystem

    collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

  • Dr. Roger Sunahara | Dr. GPCR Ecosystem

    bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

  • Dr. Nicolas Gilles | Dr. GPCR Ecosystem

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Dr. Christel Menet | Dr. GPCR Ecosystem

    I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

  • Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore | Dr. GPCR Ecosystem

    He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

  • Dr. Graeme Milligan | Dr. GPCR Ecosystem

    Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

  • A Brief History of allosteric modulation with Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

  • Eurofins DiscoverX | Dr. GPCR | Dr. GPCR Ecosystem

    Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics expertise and provides you with product solutions including cell-based assays for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics

  • Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls | Dr. GPCR Ecosystem

    Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic

  • Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem

    Whether a 20% reduction in beta-arrestin coupling matters therapeutically depends on the cell type, the drug response differences, and a largely unexplored opportunity in existing drug pipelines Antibody therapeutics Antibody therapeutics for GPCRs: the pipeline argument Biologics have a substantially higher success The combination of those two facts, Gilchrist argues, makes antibody-based GPCR therapeutics an underexplored The precedent of drugging a receptor without knowing what activates it naturally, and getting therapeutic

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

  • Dr. Juan JosĂ© Fung | Dr. GPCR Ecosystem

    Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Unlock the Full Dr.

  • Terry HĂ©bert | Dr. GPCR Ecosystem

    Hebert's argument — that challenge trials depend on a reliable therapeutic the field did not yet have Challenge trials and the therapeutic floor — Why the ethics of accelerating vaccine trials depend on challenge trial — where volunteers receive placebo or active virus — is ethically unworkable without a therapeutic Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

  • Dr. AurĂ©lien Rizk | Dr. GPCR Ecosystem

    the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

  • Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem

    The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic The review was accepted at Clinical Pharmacology and Therapeutics within weeks. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "

  • Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem

    He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

  • Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic | Dr. GPCR Ecosystem

    The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to

  • Dr. Rosie Dawaliby | Dr. GPCR Ecosystem

    In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Dr. Katarina Nemec | Dr. GPCR Ecosystem

    I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

  • Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem

    Listeners gain insight into how basic GPCR pharmacology can translate into therapeutic strategies targeting He is also an entrepreneur and founder of biotechnology companies translating GPCR pharmacology into therapeutic GPCR signaling complexity and pathway selectivity Translating receptor pharmacology into metabolic therapeutics One is Sigrid Therapeutics, which focuses on digestion and metabolic regulation. That makes them unsuitable as long-term therapeutic drugs.

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

bottom of page